Founded
2020
Revenue
$100M+
Units Sold
1.6M+
Countries
35
Retail Locations
2,265+
Subscribers
50,000+
Brand overview
Arrae launched in March 2020, founded by Siff Haider and Nish Samantray — a husband-and-wife team who funded the business with $484K they had saved for their wedding. They ran operations out of a 400-square-foot Toronto apartment, packing orders themselves in the early months.
Siff came to the brand through her own experience with chronic illness and bloating — she had spent years cycling through conventional medicine before finding relief through natural remedies. Nish brought a background in technical product management and operations. The division worked: Siff built the brand identity and community, Nish handled logistics, finance, and growth strategy.
The premise is deliberately narrow: solve one problem per product, make it work fast, and make the packaging good enough to sit on a counter instead of being shoved in a cabinet. Their first product, Bloat, went from zero to $1 million in revenue in nine months. By year five, the brand had crossed nine figures with minimal outside investment and a team of 33.
Headquarters
Los Angeles, CA (founders) · Dayton, NJ (distribution)
Founded
March 2020
Founders
Siff Haider & Nish Samantray
Manufacturing
USA & Canada, cGMP-certified
Target audience
Women 25–45, millennial wellness
Retail presence
GNC, Vitamin Shoppe + 2,265 locations
Flagship product
Bloat (2,800+ reviews)
Notable collab
Pamela Anderson for MB-1 45+
Quick verdict
What works
- Short, readable ingredient lists — no 25-ingredient prop blends
- Filler-free in practice — hypromellose capsule is the only 'other ingredient' on most products
- Retail-qualified — sold at GNC and Vitamin Shoppe, which run their own supplier vetting
- Real founder story with verifiable financial skin in the game
- Clean FDA record since 2020 launch
Watch out for
- No independent product-level certification (NSF, USP, Informed Sport, BSCG)
- Calm's key ingredient doses (L-Theanine, Inositol) hidden inside a proprietary blend — amounts undisclosed
- Clinical study underpinning headline claims was a 35-person, open-label, industry-sponsored trial — not a placebo-controlled RCT
- MB-1 "natural GLP-1 support" framing extrapolates from preclinical and proxy data
- Premium price-per-serving difficult to justify on formula alone for several products
Certifications & testing
cGMP Certified Facilities
Confirmed
Manufactured in cGMP-certified facilities in the USA and Canada.
NSF Certified for Sport
Not certified
No NSF product-level certification found. Confirmed absent.
USP Verified
Not certified
No USP Dietary Supplement Verification found.
Informed Sport / Choice
Not certified
No Informed Sport or Informed Choice certification found.
Third-Party Batch Testing
Partial — self-reported
Brand reports FTIR identity testing, heavy metals, and microbiological testing per batch. No independent body publishes or verifies these results.
FDA Record
Confirmed
No warning letters, recalls, or significant adverse event reports on file.
Arrae reports FTIR identity testing, heavy metal analysis, and microbiological testing on every batch. These are real and useful processes. However, they are self-reported — no independent certifying body publishes or verifies these results. The distinction matters: batch testing catches contamination and basic identity fraud. It does not independently verify that the label doses of active ingredients are present and accurate, which is what NSF, USP, and similar programs specifically address.
On the clinical claims
Arrae's headline figures — “86% reduction in bloating,” “74% of participants reported fewer IBS symptoms” — come from a single clinical study conducted by Citrus Labs, a company whose business model is running product efficacy trials for consumer brands. The study enrolled 35 women over 18, ran for eight weeks, and used an open-label, single-arm observational design. There was no placebo group and no blinding.
A further detail worth noting: the 86% figure specifically reflects the combined Bloat + Calm result (weeks five through eight), not Bloat alone. Bloat-only results were lower. Arrae's marketing does not always make this distinction clear.
A second, more rigorous study is registered on ClinicalTrials.gov (NCT07370740) — a randomised, placebo-controlled design run with KGK Science. It covers Bloat's effect on postprandial gas and bloating at the 60-minute mark. Results have not been published as of May 2026.
Study design
Single-arm observational
Sample size
35 women
Sponsor
Industry (Citrus Labs)
Control group
None
Blinding
Open-label
New RCT pending
NCT07370740
Full product lineup
Reviewed products
Common questions
Arrae is a well-built brand in a legitimate product category. The formulas are short and legible. The manufacturing is credible. The founder story is real and the business has scaled without the kind of quality shortcuts that usually accompany rapid DTC growth. These are not small things in an industry full of proprietary-blend noise.
The honest limitations are also real. The absence of independent product-level certification means you are trusting the brand's own quality claims — which may be accurate, but cannot be independently verified. Key doses in Calm are hidden inside a proprietary blend. The clinical study underpinning headline claims is industry-sponsored and lacks a placebo arm. MB-1's GLP-1 positioning overstates what the evidence currently supports.
Silver tier reflects a brand that is genuinely better than average — not a brand that has earned full trust across its range. Individual product reviews will assign specific scores. If the pending RCT for Bloat publishes with strong results, that assessment moves up.